Human Insulin Drugs Market in Brazil to Record 3.30% of Y-O-Y Growth Rate in 2022 | The rising prevalence of diabetes in Brazil to boost market growth| Technavio

NEW YORK, March 4, 2022 /PRNewswire/ — Human Insulin Drugs Market in Brazil Facts at a Glance-

  • Total Pages: 120
  • Companies: 10+ – Including Biocon Ltd., Boston Scientific Corp., Eli Lilly and Co., EUROFARMA LABORATORIOS SA, Gulf Pharmaceutical Industries, Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Sanofi SA, and Wockhardt Ltd. among others.
  • Coverage: Key drivers, trends, and challenges; Product insights & news; Value chain analysis; Parent market analysis; Vendor landscape.
  • Segments: Segmentation by product (basal insulin analogy and NPH), application (type I diabetes and type II diabetes), and distribution channel (retail and hospitals)

To understand more about Market Dynamics. Download our FREE sample report

According to the recent market study by Technavio, the Human Insulin Drugs Market in Brazil is expected to increase by USD 137.41 million from 2021 to 2026, at an accelerated CAGR of 5.44%. The report provides a detailed analysis of drivers & opportunities, top winning strategies, competitive scenario, future market trends, market size & estimations, and major investment pockets.

Download FREE Sample: for additional information about market size, CAGR, and Y-O-Y growth in Brazil

Vendor Insights-

The Human Insulin Drugs Market in Brazil is fragmented, and the vendors are deploying growth strategies such as focusing on product delivery through multiple distribution channels to compete in the market.

Biocon Ltd.- The company offers human insulin drugs namely Insugen

Boston Scientific Corp. – The company offers human insulin drugs namely TAXUS Express.

Eli Lilly and Co. – The company offers human insulin drugs such as Basaglar, Humalog among others.

Find additional highlights on the vendors and their product offerings. Download Free Sample Report

Human Insulin Drugs Market in Brazil Value Chain Analysis

In order to optimize profit margins and evaluate company plans, an end-to-end understanding of the value chain is required. During the projected period, the data in our value chain analysis segment can assist vendors to reduce costs and improve customer service.

The value chain of the global pharmaceuticals market includes the following core components:

  • Research and development (R&D) and drug discovery
  • Integration and product development
  • Manufacturing
  • Outbound logistics
  • Marketing and sales
  • Support activities
  • Innovation

The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.

Download our FREE sample report for more key highlights on the value chain analysis of most of the above-mentioned countries.

Latest Drivers & Trends Driving the Market-

  • Human Insulin Drugs Market in Brazil Key Driver:
    • The rising prevalence of diabetes in Brazil:

Approximately 39% of the population was incorrectly diagnosed with the disease. Furthermore, according to the survey, Brazil has the greatest number of diabetes patients of all the countries in the region. According to the study, roughly 12 million people in Brazil have diabetes, with prevalence ranging from 6.3 percent to 13.5 percent depending on the area in 2021. As a result, the human insulin medicines market has risen at a moderate rate over the last decade and is likely to do so again in the coming years.

  • Human Insulin Drugs Market in Brazil Key Trend:
    • The advent of biosimilars:

Biosimilars are manufactured using a similar, but not identical, manufacturing technique to that of the original patent holder. Biosimilar insulin medicines will thus have the same amino acid sequence as biologic insulin drugs. Biosimilars would allow vendors to profit from the therapeutic outcomes of currently available insulin medications at a considerably reduced cost, hence boosting the accessibility and affordability of human insulin therapies for diabetes treatment.

Find additional information about various other market Drivers & Trends mentioned in our FREE sample report.

Didn’t Find What You Were Looking For? Customize Report-

Don’t miss out on the opportunity to speak to our analyst and know more insights about this market report. Our analysts can also help you customize this report according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer USD 1,000 worth of FREE customization at the time of purchase. Speak to our Analyst now!

Here are Some Similar Topics-

Haemostasis Diagnostics Market by End-user and Geography – Forecast and Analysis 2022-2026: The haemostasis diagnostics market share is expected to increase by USD 1.12 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 7.95%. Download Exclusive Free Sample Report

New Drug Delivery Systems Market by Route of Administration and Geography – Forecast and Analysis 2022-2026: The new drug delivery systems market share is expected to increase by USD 77.29 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 6.08%. Download Exclusive Free Sample Report

Human Insulin Drugs Market Scope in Brazil

Report Coverage


Page number


Base year


Forecast period


Growth momentum & CAGR

Accelerate at a CAGR of 5.44%

Market growth 2022-2026

$ 137.41 million

Market structure


YoY growth (%)


Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Biocon Ltd., Boston Scientific Corp., Eli Lilly and Co., EUROFARMA LABORATORIOS SA, Gulf Pharmaceutical Industries, Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Sanofi SA, and Wockhardt Ltd.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of Contents

1. Executive Summary                         

               1.1 Market Overview 

                              Exhibit 01:  Key Finding 1

                              Exhibit 02:  Key Finding 2

                              Exhibit 03:  Key Finding 5

                              Exhibit 04:  Key Finding 6

                              Exhibit 05:  Key Finding 7

                              Exhibit 06:  Key Finding 8

2. Market Landscape                            

               2.1 Market ecosystem             

                              Exhibit 07:  Parent market

                              Exhibit 08:  Market Characteristics

               2.2 Value chain analysis           

                              Exhibit 09:  Value chain analysis: Pharmaceuticals

                              2.2.1    Research and development (R&D) and drug discovery

                              2.2.2    Integration and product development

                              2.2.3    Manufacturing

                              2.2.4    Outbound logistics

                              2.2.5    Marketing and sales

                              2.2.6    Support services

                              2.2.7    Innovation

3. Market Sizing                      

               3.1 Market definition

                              Exhibit 10:  Offerings of vendors included in the market definition

               3.2 Market segment analysis  

                              Exhibit 11:  Market segments

               3.3 Market size 2021 

               3.4 Market outlook: Forecast for 2021 – 2026 

                              3.4.1    Estimating growth rates for emerging and high-growth markets

                              3.4.2    Estimating growth rates for mature markets

                              Exhibit 12:  Brazil – Market size and forecast 2021 – 2026 ($ million)

                              Exhibit 13:  Brazil market: Year-over-year growth 2021 – 2026 (%)

4. Five Forces Analysis                         

               4.1 Five Forces Summary         

                              Exhibit 14: Five forces analysis 2021 & 2026

               4.2 Bargaining power of buyers            

                              Exhibit 15: Bargaining power of buyers

               4.3 Bargaining power of suppliers        

                              Exhibit 16: Bargaining power of suppliers

               4.4 Threat of new entrants     

                              Exhibit 17: Threat of new entrants

               4.5 Threat of substitutes          

                              Exhibit 18: Threat of substitutes

               4.6 Threat of rivalry   

                              Exhibit 19: Threat of rivalry

               4.7 Market condition 

                              Exhibit 20:  Market condition – Five forces 2021

5. Market Segmentation by Product              

               5.1 Market segments

                              The segments covered in this chapter are:

  • Basal insulin analog
  • NPH

                              Exhibit 21:  Product – Market share 2021-2026 (%)

               5.2     Comparison by Product 

                              Exhibit 22:  Comparison by Product

               5.3     Basal insulin analog – Market size and forecast 2021-2026             

                              Exhibit 23:  Basal insulin analog – Market size and forecast 2021-2026 ($ million)

                              Exhibit 24:  Basal insulin analog – Year-over-year growth 2021-2026 (%)

               5.4     NPH – Market size and forecast 2021-2026           

                              Exhibit 25:  NPH – Market size and forecast 2021-2026 ($ million)

                              Exhibit 26:  NPH – Year-over-year growth 2021-2026 (%)

               5.5     Market opportunity by Product 

                              Exhibit 27:  Market opportunity by Product

6. Market Segmentation by Application                       

               6.1 Market segments

                              The segments covered in this chapter are:

  • Type I diabetes
  • Type II diabetes

                              Exhibit 28:  Application – Market share 2021-2026 (%)

               6.2     Comparison by Application          

                              Exhibit 29:  Comparison by Application

               6.3     Type I diabetes – Market size and forecast 2021-2026      

                              Exhibit 30:  Type I diabetes – Market size and forecast 2021-2026 ($ million)

                              Exhibit 31:  Type I diabetes – Year-over-year growth 2021-2026 (%)

               6.4     Type II diabetes – Market size and forecast 2021-2026     

                              Exhibit 32:  Type II diabetes – Market size and forecast 2021-2026 ($ million)

                              Exhibit 33:  Type II diabetes – Year-over-year growth 2021-2026 (%)

               6.5     Market opportunity by Application          

                              Exhibit 34:  Market opportunity by Application

7 Market Segmentation by Distribution channel                      

               7.1     Market segments            

                              The segments covered in this chapter are:

  • Retail
  • Hospitals

                              Exhibit 35:  Distribution channel – Market share 2021-2026 (%)

               7.2     Comparison by Distribution channel        

                              Exhibit 36:  Comparison by Distribution channel

               7.3     Retail – Market size and forecast 2021-2026         

                              Exhibit 37:  Retail – Market size and forecast 2021-2026 ($ million)

                              Exhibit 38:  Retail – Year-over-year growth 2021-2026 (%)

               7.4     Hospitals – Market size and forecast 2021-2026  

                              Exhibit 39:  Hospitals – Market size and forecast 2021-2026 ($ million)

                              Exhibit 40:  Hospitals – Year-over-year growth 2021-2026 (%)

               7.5     Market opportunity by Distribution channel        

                              Exhibit 41:  Market opportunity by Distribution channel

8 Customer landscape                         

               8.1     Overview            

                              Exhibit 42:  Customer landscape

9. Drivers, Challenges, and Trends                  

               9.1 Market drivers      

                              9.1.1    Rising prevalence of diabetes in Brazil

                              9.1.2    Demographic transition in Brazil

                              9.1.3    Strategic alliances

               9.2 Market challenges              

                              9.2.1    High cost of human insulin drugs

                              9.2.2    Unknown etiology of type I diabetes

                              9.2.3    Unavailability of specific biomarkers

                              Exhibit 43:  Impact of drivers and challenges

               9.3 Market trends      

                              9.3.1    Advent of biosimilars

                              9.3.2    Increasing initiatives by vendors

                              9.3.3    Technological advancements

10. Vendor Landscape                         

               10.1   Overview            

                              Exhibit 44:  Vendor landscape

               10.2   Landscape disruption     

                              Exhibit 45:  Landscape disruption

                              Exhibit 46:  Industry risks

11. Vendor Analysis               

               11.1 Vendors covered              

                              Exhibit 47:  Vendors covered

               11.2 Market positioning of vendors    

                              Exhibit 48:  Market positioning of vendors

               11.3   Biocon Ltd.        

                              Exhibit 49:  Biocon Ltd. – Overview

                              Exhibit 50:  Biocon Ltd. – Business segments

                              Exhibit 51:  Biocon Ltd. – Key News

                              Exhibit 52:  Biocon Ltd. – Key offerings

                              Exhibit 53:  Biocon Ltd. – Segment focus

               11.4   Boston Scientific Corp.  

                              Exhibit 54:  Boston Scientific Corp. – Overview

                              Exhibit 55:  Boston Scientific Corp. – Business segments

                              Exhibit 56:  Boston Scientific Corp. – Key offerings

                              Exhibit 57:  Boston Scientific Corp. – Segment focus

               11.5   Eli Lilly and Co. 

                              Exhibit 58:  Eli Lilly and Co. – Overview

                              Exhibit 59:  Eli Lilly and Co. – Business segments

                              Exhibit 60:  Eli Lilly and Co. – Key News

                              Exhibit 61:  Eli Lilly and Co. – Key offerings

                              Exhibit 62:  Eli Lilly and Co. – Segment focus

               11.6   EUROFARMA LABORATORIOS SA              

                              Exhibit 63:  EUROFARMA LABORATORIOS SA – Overview

                              Exhibit 64:  EUROFARMA LABORATORIOS SA – Product and service

                              Exhibit 65:  EUROFARMA LABORATORIOS SA – Key offerings

               11.7   Gulf Pharmaceutical Industries   

                              Exhibit 66:  Gulf Pharmaceutical Industries – Overview

                              Exhibit 67:  Gulf Pharmaceutical Industries – Product and service

                              Exhibit 68:  Gulf Pharmaceutical Industries – Key offerings

               11.8   Merck and Co. Inc.         

                              Exhibit 69:  Merck and Co. Inc. – Overview

                              Exhibit 70:  Merck and Co. Inc. – Business segments

                              Exhibit 71:  Merck and Co. Inc. – Key offerings

                              Exhibit 72:  Merck and Co. Inc. – Segment focus

                              Exhibit 83:  Mahaphant Fiber Cement Pvt. Ltd. – Key offerings

               11.9   Novartis AG       

                              Exhibit 73:  Novartis AG – Overview

                              Exhibit 74:  Novartis AG – Business segments

                              Exhibit 75:  Novartis AG – Key offerings

                              Exhibit 76:  Novartis AG – Segment focus

               11.10 Novo Nordisk AS            

                              Exhibit 77:  Novo Nordisk AS – Overview

                              Exhibit 78:  Novo Nordisk AS – Business segments

                              Exhibit 79:  Novo Nordisk AS – Key offerings

                              Exhibit 80:  Novo Nordisk AS – Segment focus

               11.11 Sanofi SA           

                              Exhibit 81:  Sanofi SA – Overview

                              Exhibit 82:  Sanofi SA – Business segments

                              Exhibit 83:  Sanofi SA – Key offerings

                              Exhibit 84:  Sanofi SA – Segment focus

               11.12 Wockhardt Ltd.

                              Exhibit 85:  Wockhardt Ltd. – Overview

                              Exhibit 86:  Wockhardt Ltd. – Business segments

                              Exhibit 87:  Wockhardt Ltd. – Key offerings

                              Exhibit 88:  Wockhardt Ltd. – Segment focus

12. Appendix                           

               12.1 Scope of the report         

                              12.1.1 Market definition

                              12.1.2 Objective

                              12.1.3 Notes and caveats

               12.2 Currency conversion rates for US$            

                              Exhibit 89:  Currency conversion rates for US$

               12.3 Research Methodology   

                              Exhibit 90:  Research Methodology

                              Exhibit 91:  Validation techniques employed for market sizing

                              Exhibit 92:  Information sources

               12.4 List of abbreviations        

                              Exhibit 93:  List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]

SOURCE Technavio

Human Insulin Drugs Market in Brazil to Record 3.30% of Y-O-Y Growth Rate in 2022 | The rising prevalence of diabetes in Brazil to boost market growth| Technavio WeeklyReviewer

PR Newswire Science News

Earnings Disclosure

WeeklyReviewer earns primarily through affiliates and ads. We don’t encourage anyone to click on ads for any other purpose but your own. We recommend products and services often for our readers, and through many we will earn commissions through affiliate programs.

WeeklyReviewer earns commissions through affiliates of qualifying products through Amazon Associates, Fiverr Affiliates, Hostgator Affiliates, Namecheap Affiliates, NordVPN Affiliates, Semrush Affiliates, Alibaba Affiliates, Clickfunnels Affiliate, Leadpages Affiliates, Cryptohopper Affiliates, Binance Affiliates and more.

Clicking on links in WeeklyReviewer may or may not provide us commission through any qualifying purchases.

World Reviewer Staff
World Reviewer Staff
The first logical thought has to be "no way". I'm the World Observer! Ill find and share important news all day.

Latest articles

Related articles